Activation of human cytochrome P-450 3A4-catalyzed meloxicam 5'- methylhydroxylation by quinidine and hydroquinidine in vitro

Journal of Pharmacology and Experimental Therapeutics

Volumn 290, Issue 1, 1999, Pages 1-8

  Ludwig, Eva ^a   Schmid, Jochen ^a   Beschke, Klaus ^a   Ebner, Thomas ^a  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DIHYDROQUINIDINE; MELOXICAM; NIFEDIPINE; QUINIDINE; TESTOSTERONE;

ARTICLE; BINDING SITE; CATALYSIS; CHROMATOGRAPHY; COMPETITIVE INHIBITION; CONTROLLED STUDY; DRUG ACTIVATION; DRUG ACTIVITY; DRUG EFFECT; DRUG HYDROXYLATION; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; ENZYME BINDING; HUMAN; HUMAN CELL; KINETICS; PRIORITY JOURNAL;

CALCIUM CHANNEL BLOCKERS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 ENZYME SYSTEM; ENZYME ACTIVATION; HUMANS; HYDROXYLATION; MICROSOMES, LIVER; MIXED FUNCTION OXYGENASES; NIFEDIPINE; OXIDATION-REDUCTION; QUINIDINE; TESTOSTERONE 5-ALPHA-REDUCTASE; THIAZINES; THIAZOLES;

EID: 0033045179     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Baldwin SJ, Bloomer JC, Smith GJ, Ayrton AD, Clarke SE and Chenery RJ (1995) Ketoconazole and sulfaphenazole as the respective selective inhibitors of P450 3A and 2C9. Xenobiotica 25:261-270.
2. Buening MK, Chang RL, Huang MT, Fortner JG, Wood AW and Conney AH (1981) Activation and inhibition of benzo(a)pyrene and aflatoxin B1 metabolism in human liver microsomes by naturally occurring flavonoids. Cancer Res 41:67-72.
3. Chang TK, Gonzalez FJ and Waxman DJ (1994) Evaluation of triacetyloleandomycin, α-naphthoflavone and diethyldithiocarbamate as selective chemical probes for inhibition of human cytochromes P450. Arch Biochem Biophys 311:437-442.
4. Chesne C, Guyomard C, Guillouzo A, Schmid J, Ludwig E and Sauter T (1998) Metabolism of meloxicam in human liver involves cytochromes P450 2C9 and 3A4. Xenobiotica 28:1-13.
5. Engelhardt G, Homma D, Schlegel K, Utzmann R and Schnitzler C (1995) Anti-inflammatory, analgesic, antipyretic and related properties of meloxicam, a new non-steroidal anti-inflammatory agent with favourable gastrointestinal tolerance. Inflamm Res 44:423-433.
6. Feierman DE and Lasker JM (1996) Metabolism of fentanyl, a synthetic opioid analgesic, by human liver microsomes: Role of CYP3A4. Drug Metab Dispos 24:932-939.
7. Guengerich FP, Martin MV, Beaune PH, Kremers P, Wolff T and Waxman DJ (1986a) Characterization of rat and human liver microsomal cytochrome P450 forms involved in nifedipine oxidation, a prototype for genetic polymorphism in oxidative drug metabolism. J Biol Chem 261:5051-5060.
8. Guengerich FP, Müller-Enoch D and Blair IA (1986b) Oxidation of quinidine by human liver cytochrome P450. Mol Pharmacol 30:287-295.
9. Huang MT, Chang RL, Fortner JG and Conney AH (1981) Studies on the mechanism of activation of microsomal benzo[a]pyrene hydroxylation by flavonoids. J Biol Chem 256:6829-6836.
10. Jack DB (1992) Handbook of Clinical Pharmacokinetic Data, Macmillan Publishers Ltd., Basingstoke.
11. Jurima-Romet M, Crawford K, Cyr T and Inaba T (1994) Terfenadine metabolism in human liver: In vitro inhibition by macrolide antibiotics and azole antifungals. Drug Metab Dispos 22:849-857.
12. Korzekwa KR, Krishnamachary N, Shou M, Ogai A, Parise RA, Rettie AE, Gonzalez FJ and Tracy TS (1998) Evaluation of atypical cytochrome P450 kinetics with two-substrate models: Evidence that multiple substrates can simultaneously bind to cytochrome P450 active sites. Biochemistry 37:4137-4147.
13. 2 inhibitor seratrodast (ABT-001). Drug Metab Dispos 25: 110-115.
14. Maurice M, Pichard L, Daujat M, Fabre I, Joyeux H, Domergue J and Maurel P (1992) Effects of imidazole derivatives on cytochromes P450 from human hepatocytes in primary culture. FASEB J 6:752-758.
15. Newton DJ, Wang RW and Lu AY (1995) Cytochrome P450 inhibitors: Evaluation of specificities in the in vitro metabolism of therapeutic agents by human liver microsomes. Drug Metab Dispos 23:154.
16. Pichard L, Fabre I, Fabre G, Domergue J, Saint Aubert B, Mourad G and Maurel P (1990) Cyclosporin A drug interactions: Screening for inducers and inhibitors of cytochrome P-450 (cyclosporin A oxidase) in primary cultures of human hepatocytes and in liver microsomes. Drug Metab Dispos 18:595-606.
17. Schmid J and Roth W (1987) HPLC procedures for drug metabolism studies: The potential of column switching, in Drug Metabolism: From Molecules to Man (Benford DJ, Bridges JW and Gibson GG eds) pp 213-216, Taylor & Francis, London.
18. Schmid J, Busch U, Heinzel G, Bozler G, Kaschke S and Kummer M (1995) Meloxicam: Pharmacokinetics and metabolic pattern after intravenous infusion and oral administration to healthy subjects. Drug Metab Dispos 23:1206-1213.
19. Schwab GE, Raucy JL and Johnson EF (1988) Modulation of rabbit and human hepatic cytochrome P-450-catalyzed steroid hydroxylations by alpha-naphthoflavone. Mol Pharmacol 33:493-499.
20. Segel IH (1975) Enzyme Kinetics, John Wiley & Sons, New York.
21. Shou M, Grogan J, Mancewicz JA, Krausz KW, Gonzalez FJ, Gelboin, HV and Korzekwa KR (1994) Activation of CYP3A4: Evidence for the simultaneous binding of two substrates in a cytochrome P450 active site. Biochemistry 33:6450-6455.
22. Tuerck D, Busch U, Heinzel G and Narjes H (1997) Clinical pharmacokinetics of meloxicam. Arzneimittelforschung 47:253-258.
23. Ueng YF, Kuwabara T, Chun YJ and Guengerich FP (1997) Cooperativity in oxidations catalyzed by cytochrome P450 3A4. Biochemistry 36:370-381.
24. Von Moltke LL, Greenblatt DJ, Cotreau-Bibbo MM., Duan SX, Harmatz JS and Shader RI (1994) Inhibition of desipramine hydroxylation in vitro by serotonin-reuptake-inhibitor antidepressants, and by quinidine and ketoconazole: A model system to predict drug interactions in vivo. J Pharmacol Exp Ther 268:1278-1283.
25. Wandel C, Lang CC, Cowart DC, Girard AF, Bramer S, Flockhart DA and Wood AJ (1998) Effect of CYP3A inhibition on vesnarinone metabolism in humans. Clin Pharmacol Ther 63:506-611.